Document is current
Any future updates will be listed below
-
Authors
Shimizu, Hiromichi
Fujii, Toshimitsu
Kinoshita, Kenji
Kawamoto, Ami
Hibiya, Shuji
Takenaka, Kento
Saito, Eiko
Nagahori, Masakazu
Ohtsuka, Kazuo
Watanabe, Mamoru
Okamoto, Ryuichi
- License Information
-
More Information
Article History
Received: 10 September 2021
Accepted: 22 November 2021
First Online: 23 December 2021
Declarations
:
: The authors disclose the following associations: Research Grants/Clinical Trial Funding: AbbVie (Toshimitsu Fujii, Mamoru Watanabe), Boehringer Ingelheim (Toshimitsu Fujii, Mamoru Watanabe), Celgene (Toshimitsu Fujii, Mamoru Watanabe), EA Pharma (Toshimitsu Fujii, Mamoru Watanabe), Eisai (Toshimitsu Fujii, Mamoru Watanabe), Gilead Sciences (Toshimitsu Fujii, Mamoru Watanabe), Eli Lilly (Toshimitsu Fujii, Mamoru Watanabe), Mitsubishi Tanabe Pharma (Mamoru Watanabe). Consultancy: Kissei Pharma (Masakazu Nagahori), Takeda (Masakazu Nagahori); Speaker’s Bureau: AbbVie (Toshimitsu Fujii, Masakazu Nagahori, Kazuo Ohtsuka), Ajinomoto Pharma (Toshimitsu Fujii, Mamoru Watanabe), Boehringer Ingelheim (Toshimitsu Fujii), Daiichi Sankyo (Toshimitsu Fujii), EA Pharma (Toshimitsu Fujii), Kyorin Pharma (Toshimitsu Fujii, Mamoru Watanabe), Kyowa Hakko Kirin (Toshimitsu Fujii), BMS (Toshimitsu Fujii), Nichiiko (Toshimitsu Fujii), Mitsubishi Tanabe Pharma (Kento Takenaka, Masakazu Nagahori, Mamoru Watanabe, Kazuo Ohtsuka), Kyorin (Kento Takenaka, Toshimitsu Fujii, Masakazu Nagahori, Mamoru Watanabe, Kazuo Ohtsuka), Mochida Pharma (Kento Takenaka, Mamoru Watanabe, Kazuo Ohtsuka), Nippon Kayaku (Toshimitsu Fujii, Masakazu Nagahori, Mamoru Watanabe), Kissei Pharma (Toshimitsu Fujii, Masakazu Nagahori), Asashi Kasei (Masakazu Nagahori), Zeria Pharma (Kento Takenaka, Toshimitsu Fujii, Masakazu Nagahori, Kazuo Ohtsuka), Astellas Pharma (Masakazu Nagahori), and Janssen Pharma (Toshimitsu Fujii, Masakazu Nagahori, Mamoru Watanabe). The remaining authors have no conflicts to disclose.
: This study was performed in accordance with relevant guidelines and regulations, and the Tokyo Medical and Dental University Institutional Review Board approved the study (IRB No. 20101104). All patients provided written informed consent and for patients under 18 years, patient’s parent and/or legal guardian provided written informed consent.
: Not applicable.
: The authors disclose the following associations: Research Grants/Clinical Trial Funding: AbbVie (Toshimitsu Fujii, Mamoru Watanabe), Boehringer Ingelheim (Toshimitsu Fujii, Mamoru Watanabe), Celgene (Toshimitsu Fujii, Mamoru Watanabe), EA Pharma (Toshimitsu Fujii, Mamoru Watanabe), Eisai (Toshimitsu Fujii, Mamoru Watanabe), Gilead Sciences (Toshimitsu Fujii, Mamoru Watanabe), Eli Lilly (Toshimitsu Fujii, Mamoru Watanabe), Mitsubishi Tanabe Pharma (Mamoru Watanabe). Consultancy: Kissei Pharma (Masakazu Nagahori), Takeda (Masakazu Nagahori); Speaker’s Bureau: AbbVie (Toshimitsu Fujii, Masakazu Nagahori, Kazuo Ohtsuka), Ajinomoto Pharma (Toshimitsu Fujii, Mamoru Watanabe), Boehringer Ingelheim (Toshimitsu Fujii), Daiichi Sankyo (Toshimitsu Fujii), EA Pharma (Toshimitsu Fujii), Kyorin Pharma (Toshimitsu Fujii, Mamoru Watanabe), Kyowa Hakko Kirin (Toshimitsu Fujii), BMS (Toshimitsu Fujii), Nichiiko (Toshimitsu Fujii), Mitsubishi Tanabe Pharma (Kento Takenaka, Masakazu Nagahori, Mamoru Watanabe, Kazuo Ohtsuka), Kyorin (Kento Takenaka, Toshimitsu Fujii, Masakazu Nagahori, Mamoru Watanabe, Kazuo Ohtsuka), Mochida Pharma (Kento Takenaka, Mamoru Watanabe, Kazuo Ohtsuka), Nippon Kayaku (Toshimitsu Fujii, Masakazu Nagahori, Mamoru Watanabe), Kissei Pharma (Toshimitsu Fujii, Masakazu Nagahori), Asashi Kasei (Masakazu Nagahori), Zeria Pharma (Kento Takenaka, Toshimitsu Fujii, Masakazu Nagahori, Kazuo Ohtsuka), Astellas Pharma (Masakazu Nagahori), and Janssen Pharma (Toshimitsu Fujii, Masakazu Nagahori, Mamoru Watanabe). The remaining authors have no conflicts to disclose.
